Blueprint gets first approval as FDA backs stomach cancer drugUS biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for Share XBlueprint gets first approval as FDA backs stomach cancer drughttps://pharmaphorum.com/news/blueprint-gets-first-approval-as-fda-backs-stomach-cancer-drug/
Blueprint eyes quick filing for GIST drug avapritinibBlueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set Share XBlueprint eyes quick filing for GIST drug avapritinibhttps://pharmaphorum.com/news/blueprint-eyes-quick-filing-for-gist-drug-avapritinib/
